Stuttgart - Delayed Quote EUR

IntegraGen SA (7N8.SG)

Compare
0.4600 0.0000 (0.00%)
At close: December 30 at 1:27:17 PM GMT+1
Loading Chart for 7N8.SG
DELL
  • Previous Close 0.4600
  • Open 0.4640
  • Bid 0.4600 x --
  • Ask 0.5500 x --
  • Day's Range 0.4600 - 0.4640
  • 52 Week Range 0.3860 - 0.8560
  • Volume 0
  • Avg. Volume 0
  • Market Cap (intraday) 3.741M
  • Beta (5Y Monthly) 0.19
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0000
  • Earnings Date Oct 17, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

IntegraGen SA provides researchers with sequencing solutions, data management tools, and biostatistical, and bioinformatics support services in France. The company's genomic pharma services DNA sequencing for oncology and rare disease research; and NGS testing for cancer research. It also provides MERCURY, an online biological interpretation tool for oncology intended to assist pathologists and oncologists in transforming raw data obtained through high-throughput sequencing into a molecular report for translational and clinical research use; Galileo, a cloud-based app for dynamic exporation of RNA-Seq expression data; and GeCo, a genomic consulting service that offers researchers with access to biostatistics and bioanalytics experts. IntegraGen SA was incorporated in 2000 and is headquartered in Évry, France. IntegraGen SA operates as a subsidiary of OncoDNA SA.

integragen.com

55

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 7N8.SG

View More

Performance Overview: 7N8.SG

Trailing total returns as of 12/31/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

7N8.SG
42.79%
CAC 40
2.15%

1-Year Return

7N8.SG
42.79%
CAC 40
2.15%

3-Year Return

7N8.SG
65.72%
CAC 40
2.89%

5-Year Return

7N8.SG
65.72%
CAC 40
23.38%

Compare To: 7N8.SG

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 7N8.SG

View More

Valuation Measures

As of 12/30/2024
  • Market Cap

    3.38M

  • Enterprise Value

    2.34M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.28

  • Price/Book (mrq)

    1.61

  • Enterprise Value/Revenue

    0.21

  • Enterprise Value/EBITDA

    32.70

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -1.36%

  • Return on Assets (ttm)

    0.24%

  • Return on Equity (ttm)

    -8.17%

  • Revenue (ttm)

    12.6M

  • Net Income Avi to Common (ttm)

    -171.4k

  • Diluted EPS (ttm)

    -0.0000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.88M

  • Total Debt/Equity (mrq)

    55.93%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: 7N8.SG

View More

People Also Watch